4//SEC Filing
Biller Scott 4
Accession 0001209191-19-017738
CIK 0001439222other
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 4:06 PM ET
Size
18.3 KB
Accession
0001209191-19-017738
Insider Transaction Report
Form 4
Biller Scott
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common stock
2019-03-05$31.64/sh+428$13,542→ 26,939 total - Exercise/Conversion
Common stock
2019-03-05$39.76/sh+2,572$102,263→ 29,511 total - Sale
Common stock
2019-03-05$66.45/sh−200$13,290→ 29,311 total - Sale
Common stock
2019-03-05$67.73/sh−2,600$176,098→ 26,711 total - Sale
Common stock
2019-03-05$68.22/sh−200$13,644→ 26,511 total - Exercise/Conversion
Stock option (right to buy)
2019-03-05−428→ 11,354 totalExercise: $31.64Exp: 2024-03-04→ Common stock (428 underlying) - Exercise/Conversion
Stock option (right to buy)
2019-03-05−2,572→ 42,648 totalExercise: $39.76Exp: 2026-02-15→ Common stock (2,572 underlying)
Holdings
- 53,059(indirect: See footnote)
Common stock
Footnotes (8)
- [F1]This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $66.05 to $66.85. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F4]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $67.14 to $68.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F5]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $68.14 to $68.30. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F6]Shares held by a spousal lifetime access trust, of which the reporting person's wife is the trustee.
- [F7]This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- [F8]This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Documents
Issuer
AGIOS PHARMACEUTICALS INC
CIK 0001439222
Entity typeother
Related Parties
1- filerCIK 0001581956
Filing Metadata
- Form type
- 4
- Filed
- Mar 6, 7:00 PM ET
- Accepted
- Mar 7, 4:06 PM ET
- Size
- 18.3 KB